Faculty Bibliography

Despite nearly universal agreement on the need for a vaccine to prevent AIDS, many scientists, public health officials and political leaders are sharply divided over when to begin the first large-scale trials and which product to test. A vaccine is still the main goal everywhere because prevention is better and cheaper than treatment

People attending the international meeting on AIDS in Vancouver the week of Jul 7, 1996 were confronted with a mix of hope and fear. Studies indicate that a combination of drugs can slow down HIV, but the trials have involved small numbers of individuals and have lasted less than a year

India has quickly emerged as the country with the largest number of people infected with HIV, only a few years after the AIDS virus was first detected there, the head of the UN's AIDS program said as the 11th International AIDS meeting opened in Vancouver on Jul 7, 1996

Remarkable gains in using combinations of costly new and old drugs promise to slow the progression of AIDS, if not stop it in its tracks, and to allow many people infected with HIV, the virus that causes AIDS, to live longer and healthier lives, the researchers said in interviews. Gains in prevention measures have helped avoid infection for many others in the United States, Thailand and some areas of Africa, offering hope that deterrents can work elsewhere. Health workers in Thailand calculate that by the year 2000 they will have prevented 2 million infections with HIV by controlling other sexually transmitted diseases that may increase susceptibility to AIDS infection and by educating people to practice safer sex. Their findings are among those to be presented to 15,000 participants from 125 countries at the conference. By trumpeting the gains in glowing terms in advance of the meeting, a number of leaders in AIDS research and drug companies have transformed the pessimistic mood that has prevailed at the last several international meetings to one of exuberance. The mood change reflects testimonials from some AIDS patients who seem to have bounced back from their deathbeds, and statements from researchers testing a new class of anti-HIV drugs known as protease inhibitors in combination with AZT and other drugs in industry-sponsored trials. In recent months, the Food and Drug Administration has approved the marketing of three protease inhibitors: indinavir (Crixivan), ritonavir (Norvir) and saquinavir (Invirase)

Remarkable gains in using combinations of costly new and old drugs promise to slow the progression of AIDS, if not stop it, and to allow many people infected with the human immunodeficiency virus, which causes AIDS, to live longer and healthier lives, researchers said. Gains in prevention measures have helped avoid infection for many others in the United States, Thailand and some areas of Africa, offering hope that deterrents can work elsewhere. Health workers in Thailand calculate that by 2000 they will have prevented 2 million infections with HIV by controlling other sexually transmitted diseases that may increase susceptibility to AIDS infection and by educating people to practice safer sex. Their findings are among those to be presented to 15,000 participants from 125 countries at the conference. By trumpeting the gains in glowing terms in advance of the meeting, a number of leaders in AIDS research and drug companies have transformed the pessimistic mood that has prevailed at the last several international meetings to one of exuberance. The mood change reflects testimonials from some AIDS patients who seem to have bounced back from their deathbeds, and statements from researchers testing a new class of anti-HIV drugs known as protease inhibitors in combination with AZT and other drugs in industry-sponsored trials. In recent months, the Food and Drug Administration has approved the marketing of three protease inhibitors: indinavir {Crixivan}, ritonavir {Norvir} and saquinavir {Invirase}

The 11th international AIDS meeting opens in Vancouver on Jul 6, 1996 with leading researchers' hopes high. Remarkable gains in using combinations of costly new and old drugs promise to slow the progression of AIDS, if not stop it in its tracks, and to allow many people infected with HIV, the virus that causes AIDS, to live longer and healthier lives, the researchers said

Remarkable gains in using combinations of costly new and old drugs promise to slow the progression of AIDS, if not stop it in its tracks, and to allow many people infected with HIV, the virus that causes AIDS, to live longer and healthier lives, the researchers said in interviews. Gains in prevention measures have helped avoid infection for many others in North America, Thailand and some areas of Africa, offering hope that deterrents can work elsewhere. Health workers in Thailand calculate that by the year 2000 they will have prevented 2 million infections with HIV by controlling other sexually transmitted diseases that might increase susceptibility to AIDS infection and by educating people to practice safer sex. Their findings are among those to be presented to 15,000 participants from 125 countries at the conference. By trumpeting the gains in glowing terms in advance of the meeting, a number of leaders in AIDS research and drug companies have transformed the pessimistic mood that has prevailed at the last several international meetings to one of exuberance. The mood change reflects testimonials from some AIDS patients who seem to have bounced back from their deathbeds, and statements from researchers testing a new class of anti-HIV drugs known as protease-inhibitors in combination with AZT and other drugs in industry-sponsored trials. In recent months, the U.S. Food and Drug Administration has approved the marketing of three protease-inhibitors: indinavir (Crixivan), ritonavir (Norvir) and saquinavir (Invirase)

New York City's investigation of an outbreak of an intestinal ailment caused by a microbe has created an extraordinary conflict between the Health Dept and a leading scientist, Rosemary Soave, over reporting cases of the ailment, cyclospora. Health Commissioner Margaret A. Hamburg subpoenaed records from Soave, who said that she had declined an initial request to turn over the records, citing patient confidentiality and the fact that some patients had been referred to her by other doctors

'I tell them it's Ontario. They're afraid. They think I lie to them,' he said. 'Some of them say, 'If I get sick, I'll come back to you.' I say 'Okay.' '

The Food and Drug Administration has asked six laboratories -- four of its own, one at the CDC in Atlanta and another at the California health department -- to use the as polymerase chain reaction test to try to detect cyclospora on fruit. The tests are being done on leftovers from implicated meals served in homes and restaurants, and from random samples collected from stores, distributors and growers. Investigation of the outbreaks has been further complicated by the medical novelty of cyclospora. Most doctors lack experience in diagnosing and treating cyclospora, and many laboratories do not test for it. The advisory was issued on June 8 after two clusters of people who ate the same meal at a Houston restaurant and a Houston club became ill with cyclospora infection. Some 78 cases of cyclospora have been reported in Texas, including the 10 in Austin